AR074507A1 - Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra. - Google Patents

Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra.

Info

Publication number
AR074507A1
AR074507A1 ARP090104739A ARP090104739A AR074507A1 AR 074507 A1 AR074507 A1 AR 074507A1 AR P090104739 A ARP090104739 A AR P090104739A AR P090104739 A ARP090104739 A AR P090104739A AR 074507 A1 AR074507 A1 AR 074507A1
Authority
AR
Argentina
Prior art keywords
crystalline form
nalmephene
dihydrated
chlorhydrate
alcoholism
Prior art date
Application number
ARP090104739A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H, Biotie Therapies Corp filed Critical Lundbeck & Co As H
Publication of AR074507A1 publication Critical patent/AR074507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto representado mediante la fórmula (1). Reivindicación 2: Un compuesto de acuerdo con la reivindicación 1, donde el compuesto es clorhidrato de nalmefeno dihidratado. Reivindicación 5: Un compuesto de acuerdo con la reivindicación 4, donde el compuesto en una forma cristalina se caracteriza además por un espectro de difracción de polvo de rayos X en valores 2theta empleando radiación de Cu Kalfa1 con un pico en uno o más de 10,63, 15,24, 16,55. y/o 17,20.
ARP090104739A 2008-12-05 2009-12-07 Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra. AR074507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200801729 2008-12-05

Publications (1)

Publication Number Publication Date
AR074507A1 true AR074507A1 (es) 2011-01-19

Family

ID=41571731

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104739A AR074507A1 (es) 2008-12-05 2009-12-07 Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra.

Country Status (31)

Country Link
US (2) US8530495B2 (es)
EP (2) EP2300479B1 (es)
JP (3) JP6055183B2 (es)
KR (2) KR20170008893A (es)
CN (2) CN104211707B (es)
AR (1) AR074507A1 (es)
AT (1) ATE546453T1 (es)
AU (1) AU2009321898B2 (es)
BR (1) BRPI0922774B8 (es)
CA (1) CA2744932C (es)
CL (1) CL2011001331A1 (es)
CO (1) CO6362012A2 (es)
CY (2) CY1112643T1 (es)
DK (2) DK2300479T3 (es)
EA (1) EA018948B1 (es)
ES (2) ES2488165T3 (es)
HK (1) HK1205108A1 (es)
HR (2) HRP20120247T1 (es)
IL (1) IL213112A (es)
MX (1) MX2011005865A (es)
MY (1) MY149028A (es)
NZ (1) NZ593874A (es)
PL (2) PL2441766T3 (es)
PT (2) PT2441766E (es)
RS (2) RS53415B (es)
SG (1) SG171910A1 (es)
SI (2) SI2441766T1 (es)
SM (2) SMT201200014B (es)
TW (1) TWI465450B (es)
UA (1) UA102128C2 (es)
WO (1) WO2010063292A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
JP2019031524A (ja) * 2008-12-05 2019-02-28 ハー・ルンドベック・アクチエゼルスカベット ナルメフェン塩酸塩二水和物
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005217A1 (en) * 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
WO2014170352A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
TW201625252A (zh) 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN105646508B (zh) * 2016-02-17 2018-02-27 南京卓康医药科技有限公司 一种盐酸纳美芬一水合物的制备方法
WO2019022274A1 (ko) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN113354652A (zh) * 2021-06-24 2021-09-07 无锡济煜山禾药业股份有限公司 一种盐酸纳美芬合成方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
CA2545584C (en) * 2003-11-17 2012-10-23 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
MY139797A (en) * 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
CN100536848C (zh) * 2005-07-13 2009-09-09 北京易明康元医药科技有限公司 稳定的盐酸纳美芬注射液及其制备方法
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447013A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
PL2147920T3 (pl) * 2007-03-06 2017-02-28 Mallinckrodt Llc Sposób wytwarzania czwartorzędowych N-alkilowych soli alkaloidu morfinanowego
EP2139897A1 (en) * 2007-04-12 2010-01-06 Mallinckrodt Inc. Crystalline and amorphous forms of naltrexone hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Also Published As

Publication number Publication date
JP6591759B2 (ja) 2019-10-16
JP2015134785A (ja) 2015-07-27
HRP20140648T1 (hr) 2014-09-26
US20110251228A1 (en) 2011-10-13
AU2009321898A1 (en) 2011-07-14
HRP20120247T1 (hr) 2012-05-31
EP2441766A1 (en) 2012-04-18
EP2441766B1 (en) 2014-06-25
CN102325778B (zh) 2014-08-13
CN104211707B (zh) 2017-04-12
ATE546453T1 (de) 2012-03-15
CA2744932C (en) 2013-05-07
CN104211707A (zh) 2014-12-17
KR20110089333A (ko) 2011-08-05
PL2300479T3 (pl) 2012-06-29
SI2441766T1 (sl) 2014-12-31
ES2380297T3 (es) 2012-05-10
JP2017025079A (ja) 2017-02-02
US8530495B2 (en) 2013-09-10
WO2010063292A1 (en) 2010-06-10
EP2300479A1 (en) 2011-03-30
SMT201400113B (it) 2014-11-10
EP2300479B1 (en) 2012-02-22
SG171910A1 (en) 2011-07-28
RS52255B (en) 2012-10-31
JP2012510954A (ja) 2012-05-17
CO6362012A2 (es) 2012-01-20
EA201170753A1 (ru) 2011-12-30
US20130338365A1 (en) 2013-12-19
PT2441766E (pt) 2014-08-05
TW201022273A (en) 2010-06-16
EA018948B1 (ru) 2013-11-29
CY1112643T1 (el) 2016-02-10
NZ593874A (en) 2013-02-22
DK2441766T3 (da) 2014-07-21
CN102325778A (zh) 2012-01-18
US8754217B2 (en) 2014-06-17
BRPI0922774B1 (pt) 2020-10-13
PL2441766T3 (pl) 2014-09-30
KR20170008893A (ko) 2017-01-24
IL213112A (en) 2013-06-27
HK1205108A1 (en) 2015-12-11
MY149028A (en) 2013-06-28
SMT201200014B (it) 2012-07-10
ES2488165T3 (es) 2014-08-26
JP6591944B2 (ja) 2019-10-16
AU2009321898B2 (en) 2014-10-02
SI2300479T1 (sl) 2012-07-31
CA2744932A1 (en) 2010-06-10
DK2300479T3 (da) 2012-03-26
RS53415B (en) 2014-12-31
IL213112A0 (en) 2011-07-31
TWI465450B (zh) 2014-12-21
CL2011001331A1 (es) 2011-08-26
PT2300479E (pt) 2012-04-10
BRPI0922774B8 (pt) 2021-05-25
CY1115381T1 (el) 2017-01-04
UA102128C2 (en) 2013-06-10
BRPI0922774A2 (pt) 2017-07-11
JP6055183B2 (ja) 2016-12-27
MX2011005865A (es) 2011-09-06

Similar Documents

Publication Publication Date Title
AR074507A1 (es) Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra.
CA2875877C (en) Syk inhibitors
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA200601274A1 (ru) Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
RU2013109393A (ru) Безилатная соль ингибитора втк
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
AR076974A1 (es) Metodo para sintetizar pirfenidona
TN2012000248A1 (en) Novel spiropiperidine compounds
MX2015010698A (es) Derivado de piridina monociclico.
CY1116086T1 (el) Ενυδρη υδροχλωρικη αγομελατινη και παρασκευη αυτης
GEP20074106B (en) Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MY192027A (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
CR20130594A (es) Monohidrato de derivados de aza-adamantano
HK1146710A1 (en) Radiopharmaceutical composition
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
AR076856A1 (es) Lenalidomida polimorfa y proceso para su preparacion
JOP20200030A1 (ar) مركب خماسي الحلقة
EA201270302A1 (ru) Безводные формы производных пиридина

Legal Events

Date Code Title Description
FB Suspension of granting procedure